Table 1.

Current indications of tocilizumab.

Autoimmune/ inflammatory condition	U.S. Food and Drug Administration (FDA)	FDA administration route	European Medicines Agency (EMA)	EMA administration route
RA	Adults with active RA and inadequate response to DMARDs	IV or SC	Adults with severe RA and inadequate response to methotrexate, or with moderate to severe active RA not responding to DMARDs or TNF blockers	IV or SC
Systemic JIA	Patients ≥ 2 years with active disease	IV	Patients ≥ 1 year with poor response to NSAIDs and GC	IV
Polyarticular JIA	Patients ≥ 2 years with active disease	IV	Patients ≥ 2 years with active disease, not responding to methotrexate	IV or SC
GCA	Adult patients	SC	Adult patients	SC
CRS due to CAR-T cell therapy	Adults and pediatric patients ≥2 years with CAR T cell-induced severe or life-threatening CRS	IV	Adults and pediatric patients ≥2 years with CAR T cell-induced severe or life-threatening CRS	IV

Abbreviations: CAR = Chimeric antigen receptor; CRS = Cytokine release syndrome; DMARDs = Disease modifying anti-rheumatic drugs; GC = Glucocorticoids; GCA = Giant cell arteritis; IV = Intravenous; JIA = Juvenile idiopathic arthritis; NSAIDs = Non-steroidal anti-inflammatory drugs; RA = Rheumatoid arthritis; SC = Subcutaneous; TNF = Tumor necrosis factor.